A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Inclusion Criteria:

• Participants who previously participated in N01269 (NCT04666610) and qualify forentry into EP0132 as per N01269 (NCT04666610) protocol with a confirmed diagnosis ofchildhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE), and for whom areasonable benefit from long-term administration of brivaracetam (BRV) is expected,in the opinion of the Investigator

• A sexually active male study participant must agree to use contraception during thetreatment period and for at least 2 days, corresponding to the time needed toeliminate study treatment, after the last dose of study treatment and refrain fromdonating sperm during this period

• A female study participant is eligible to participate if she is not pregnant, notbreastfeeding, and at least 1 of the following conditions applies:

1. The study participant is premenarchal OR

2. A woman of childbearing potential (WOCBP) who agrees to follow thecontraceptive guidance during the treatment period and for at least 2 daysafter the last dose of study medication, corresponding to the time needed toeliminate study treatment

• Study participant is capable of and provides consent/assent, and the studyparticipant's parent/legal representative/caregiver provides signed informed consentfor minor study participants, which includes compliance with the requirements andrestrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

• Study participant has a history or presence of paroxysmal nonepileptic seizures

• Study participant has severe medical, neurological, or psychiatric disorders orlaboratory values, which could, at the discretion of the Investigator, affect safeparticipation in the study or would preclude appropriate study participation

• Study participant has a clinically relevant electrocardiogram (ECG) abnormality inthe opinion of the Principal Investigator

• Study participant has hepatic impairment (Child Pugh Score A, B, or C) based on theInvestigator's assessment

• Study participant has active suicidal ideation prior to study entry as indicated bya positive response ("Yes") to either Question 4 or Question 5 of the ColumbiaSuicide Severity Rating Scale (C-SSRS) (for study participants 6 years or older) orclinical judgment (for study participants younger than 6 years). The studyparticipant should be referred immediately to a Mental Healthcare Professional

• Study participant has a lifetime history of suicide attempt (including an activeattempt, interrupted attempt, or aborted attempt). The Investigator must immediatelyrefer the study participant to a Mental Healthcare Professional

• Participant has any medical or psychiatric condition that, in the opinion of theInvestigator, could jeopardize or would compromise the study participant's abilityto participate in this study

• Participant has a known fructose intolerance or known hypersensitivity to anycomponents of brivaracetam (BRV) or excipients or a drug with similar chemicalstructure. Note that the tablets contain lactose

• Study participant has end-stage kidney disease requiring dialysis

• Concomitant use of carbamazepine, felbamate, gabapentin, oxcarbazepine,phenobarbital, phenytoin, tiagabine, or vigabatrin

• Study participant has planned participation in any clinical study on aninvestigational drug or device

• Study participant has poor compliance with the visit schedule or medication intakein the core study in the opinion of the Investigator